Alison M. Goate Named Chair of Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai
Noted Alzheimer’s researcher will assume new role on January 1, 2021
Alison M. Goate, DPhil, a leading scientist in neurodegenerative diseases including Alzheimer’s disease (AD) and frontotemporal dementia (FTD), has been named Chair of the Department of Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai. Dr. Goate is the Willard T.C. Johnson Research Professor of Neurogenetics, and Professor of Genetics and Genomic Sciences, Neuroscience, and Neurology. She joined the Icahn School of Medicine faculty in 2015 as Founding Director of The Ronald M. Loeb Center for Alzheimer’s Disease at Mount Sinai. She will assume her new responsibilities on January 1, 2021.
“Dr. Goate has made significant contributions in the field of genetics and we know her leadership will propel Mount Sinai’s contributions to the field of genetics and futher the understanding of many diseases,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of Mount Sinai Health System. “We have made substantial investments in the future of genetic and genomic research which have led to developments in diagnostics and next-generation treatments We will continue this momentum under the leadership of a dynamic and visionary scientist.”
“Dr. Goate brings tremendous expertise and leadership to a team of already exceptional scientists and faculty,” said Eric J. Nestler, MD, PhD, Dean for Academic and Scientific Affairs, Director of The Friedman Brain Institute and Nash Family Professor of Neuroscience at Icahn School of Medicine at Mount Sinai. “Together, I know they will continue to shape this field and discover new and uncharted approaches to understanding and treating the most complex diseases. I am excited for this next frontier under her leadership.”
Her notable accomplishments in the field include the discovery of genetic mutations and risk factors in AD. The progress that she made in early diagnosis of this crippling disease is a game changer for physicians and patients. She is a remarkable scientist who will build upon these achievements and push the boundaries of academic medicine in genetics and genomic sciences.
“This is an extraordinary time for genomics and for this Department. We are a recognized leader in applying genomics and data science to medicine, and it is my privilege to build upon this foundation to prevent and treat human disease,” said Dr. Goate. “We have made tremendous advances in our understanding of the human genome and are poised to translate this fundamental knowledge in genomics and data science into knowledge that improves health for humanity. My vision for the Department is to be recognized as a world leader in genomics, to find solutions and make meaningful advances in human health.”
Dr. Goate has devoted her life’s work to understanding neurodegenerative disease. Over the last three decades, she has been part of many gene finding teams that have identified disease-causing variants for both AD and frontotemporal dementia. As a postdoctoral fellow at Imperial College, London, she worked with influential neurogeneticist John Hardy, PhD, and reported the first mutation to cause familial AD. She was later recruited to Washington University in St. Louis, where she led early studies that identified a mutation in Colombian families with early-onset AD. This work is now part of a larger clinical trial. Her lab was also part of the team that first reported MAPT mutations in FTD and she later led a National Institutes of Health-funded study to identify gene variants that protect against AD in people who are at greater risk for developing the disorder and whether gene variants influence the age of onset of the illness. During her tenure there, she became the Director of the Hope Center for Neurological Disorders.
Dr. Goate is a leader in the study of late-onset AD genetics using integrative genomic approaches to identify novel genetic risk factors. Her work has highlighted the enrichment of AD risk variants in microglial enhancers, regulatory elements in DNA that control gene expression in immune cells of the brain. She also leads an NIH funded study to identify gene variants that protect against AD, even in those who are at high risk for disease. She is now building upon these genetic insights using genome-editing in induced pluripotent stem cells to understand the molecular mechanisms underlying disease risk and protection to develop novel therapeutics.
Dr. Goate continued, “A fundamental understanding of the genetic basis of disease and human traits can and will lead to major changes in the way we diagnose, prevent, and treat disease across all medical specialties. My primary goal will be to build a department with a diverse workforce and an international reputation for excellence in research, education, and patient care in genomic medicine and data sciences. I look forward to working with leaders of all genetics, genomics and data science Institutes and Centers within Mount Sinai to develop an integrated vision for the future.”
Dr. Goate has received the Potamkin Award and the Khalid Iqbal Lifetime Achievement Award from the Alzheimer’s Association and the MetLife Award for her research on AD. She was elected a fellow of AAAS in 2012 and a member of the National Academy of Medicine in 2016.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Mount Sinai Microbiome Lab Joins NIH’s Accelerating Medicines Partnership
May 19, 2022 View All Press Releases
Mount Sinai Announces Expanded Capability in Medical Research
Nov 18, 2019 View All Press Releases